Tetratherix Ltd

Tetratherix operates with a fully diluted share count of 50.77 million shares, with no additional shares outstanding in the diluted scenario, indicating no immediate dilution risk from stock options or convertible instruments. The company's market capitalization is approximately AUD 371.1 million, with a current market price of AUD 7.31 per share. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. The company's valuation snapshot does not include return on invested capital (ROIC), gross margins, or operating margins, which are typically used to assess performance in the biotechnology and medical research sectors. Tetratherix's revenue concentration and geographic exposure are not disclosed in the available data. The company does not provide segment-level revenue breakdowns or geographic revenue distribution, making it difficult to assess diversification or exposure to specific markets. Growth trajectory is not quantified in the current dataset, and no numeric deltas are provided for the current or next fiscal year. Analysts have issued a mean price target of AUD 5.72, with a median of AUD 5.72, suggesting a potential downside from the current market price of AUD 7.31. The mean recommendation is 2.00, indicating a "Hold" consensus among analysts. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. Dilution risk is currently assessed as low, with no additional shares outstanding in the diluted scenario. No adjustments have been applied to the valuation metrics, and no dilution sources are disclosed in the available data. Recent events and filings are not detailed in the current dataset. No transcripts or material filings are available to assess recent corporate developments or management commentary.